Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
0.6419 ^USD	+2.65%		-1.12%	-37.07%

31/05	Lipella Pharmaceuticals Inc. Announces Completion of Site Initiation Visit for Phase 2A Trial of LP-310 in Oral Lichen Planus	CI
09/05	Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 01, 2023 at 01:24 am IST

Lipella Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 0.184156 million compared to USD 0.259347 million a year ago. Net loss was USD 2.6 million compared to USD 1.87 million a year ago.

Basic loss per share from continuing operations was USD 0.64 compared to USD 0.55 a year ago. Diluted loss per share from continuing operations was USD 0.64 compared to USD 0.55 a year ago.

Latest news about Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. Announces Completion of Site Initiation Visit for Phase 2A Trial of LP-310 in Oral Lichen Planus	31/05	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	17/04	CI
Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target	09/04	MT
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	08/12	MT
Top Premarket Decliners	08/12	MT
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease	10/11	DJ
Lipella Pharmaceuticals Inc. announced that it has received $1.998685 million in funding	25/23/25	CI
Lipella Pharmaceuticals Inc. announced that it expects to receive $1.998685 million in funding	24/23/24	CI
Sector Update: Health Care Stocks Softer Late Afternoon	21/23/21	MT
Top Midday Gainers	20/23/20	MT
Sector Update: Health Care Stocks Slightly Higher Friday Afternoon	20/23/20	MT
Sector Update: Health Care	20/23/20	MT
Lipella Pharmaceuticals Says US FDA Approves IND Status for LP-310 for Oral Lichen Planus; Shares Surge	20/23/20	MT
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	20/23/20	MT
Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	20/23/20	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Lipella Pharmaceuticals Inc. announced a financing transaction	10/23/10	CI
Lipella Pharmaceuticals Inc. Appoints Lori Birder as a Member of the Board	24/23/24	CI
Certain Options of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	17/23/17	CI
Certain Warrants of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	17/23/17	CI
Certain Preferred Stock of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	17/23/17	CI

Chart Lipella Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6419 USD

Average target price

2 USD

Spread / Average Target

+211.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIPELLA PHARMACEUTICALS INC.	-37.07%	4.88M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs